Vanke A: the contract sales amount in May was 30.76 billion yuan
Vanke A announced that in May, the company achieved a contract sales area of 1.875 million square meters and a contract sales amount of 30.76 billion yuan; From January to may, the company achieved a total contractual sales area of 9.811 million square meters and a contractual sales amount of 168.11 billion yuan.
This text is a result of machine translation.
Related companies：
Briefing Jun 24, 2022 11:33 PM
· Real Estate
RMB 12.1 billion was collected, and the second batch of 8 plots of centralized land supply in Dongguan were all sold
In-depth
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Healthcare
Trautec Medical Raises Nearly CNY 200 Mn in Series A Financing Round
Trautec Medical, dedicated to developing and producing recombinant collagen-based biomaterials, will continue to focus on the innovation of biomaterials and strive to integrate resources from all sides.
Aug 12, 2022 06:12 PM
Healthcare
Preparation Developer Elite Pharmaceutical Nets Nearly CNY 100 Mn in Series B Round
This financing round will further promote the company's R&D and clinical trials and be used to construct new production bases. The completion of the new production base will significantly improve the application efficiency of the products independently developed by Elite and reduce the cost without reducing the capacity of the products.
Aug 12, 2022 05:56 PM
Briefing Feb 12, 2022 10:39 AM
· Real Estate
Travel abroad and other private passport processing and renewal resumed? National Immigration administration: false
Briefing Jan 27, 2022 07:39 PM
Tibet Mining: it is estimated that the net profit in 2021 will be 110 million yuan - 165 million yuan to turn losses into profits
Healthcare
Aesthetic Medicine Company Tian Shi Wei Nets Tens of Millions of RMB in Series A Round
Soluble microneedle technology has received wide attention from the industry recently and is expected to be commercialized in aesthetic medicine. Tian Shi Wei gained capital preference for its R&D, mass production and quality control capabilities.
Aug 12, 2022 04:58 PM
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Insight
In-depth